Professor Brian Leonard: Former Editor-in-Chief of Human Psychopharmacology

IF 1.8 4区 医学 Q3 CLINICAL NEUROLOGY Human Psychopharmacology: Clinical and Experimental Pub Date : 2024-02-08 DOI:10.1002/hup.2894
David S. Baldwin
{"title":"Professor Brian Leonard: Former Editor-in-Chief of Human Psychopharmacology","authors":"David S. Baldwin","doi":"10.1002/hup.2894","DOIUrl":null,"url":null,"abstract":"<p>‘<i>Ní bheidh a leithéid ann arís</i>’ (‘we won't see his like again’). Thus concluded the warm tribute to Professor Brian Leonard, posted on the British Association for Psychopharmacology website, on the sad news of his passing, after a short illness, in the final week of 2023 (see www.bap.org.uk). Brian was a former President of both the BAP and the Collegium Internationale Neuropsychopharmacologicum (CINP) and served as Editor-in-Chief of <i>Human Psychopharmacology</i> between 1994 and 1999 (succeeding the Founding Editor Guy Edwards, whose obituary was published last year: see Cowen, <span>2023</span>). During his Editorship, the journal flourished in terms of its scientific content, international contributors, readership and impact.</p><p>Born in 1936, Brian became a leading figure in psychopharmacological research, education and training, over 50 years. After working at Nottingham University (1962–1968), and in the pharmaceutical industry (1968–1974, first at ICI Ltd, then Organon Laboratories), he became Founding Professor and Head of the Department of Pharmacology at University College Galway in 1974, continuing there until 1999, when he ‘retired’. He held Professor Emeritus status at the University of Galway, and a Visiting Professorship at the University of Maastricht from 2002, and an Honorary Professorship at Ludwig Maximilian University, Munich since 2007. He continued publishing scientific articles until the final months of 2023. His wide-ranging and influential research encompassed studies of anxiolytic and antidepressant compounds, the neurobiology of affective disorders, alcohol use disorders, and dementia, and he was an early pioneer in the realm of psychoneuroimmunology.</p><p>His former colleagues draw attention to his pioneering research in the development and characterisation of animal models of depression (most notably the olfactory bulbectomy model), and in preclinical studies of the pharmacology of antidepressants, anxiolytics, and other psychotropics: and his major contributions to investigating biomarkers of major psychiatric disorders, the metabolic syndrome in depression and schizophrenia, and in psychoneuroimmunology, where he was one of the first to recognise, investigate, and promote the importance of the brain-immune axis in depression and schizophrenia. He received the BAP Lifetime Achievement Award in 2008.</p><p>Brian was a truly inspirational lecturer, combining his extensive knowledge of pharmacology with panache and cheeky humour, encouraging many to pursue careers in clinical and experimental psychopharmacology and translational and applied neuroscience. After notional ‘retirement’ he travelled widely, in particular to low and middle income countries in Africa and Asia, lecturing to international colleagues and inspiring the emerging generations of academic and clinical researchers. He received the CINP Arvid Carlsson medal for education in 2012. In addition, Brian had a lifelong passion for challenging socioeconomic disadvantage, discrimination and other societal injustices, and would engage in insightful and lively political discussions whenever needed.</p><p>Brian kindly supported my research and clinical interests in anxiety and depression at a pivotal career stage; and later encouraged me to become Editor of this journal. He also invited me to contribute to his periodic psychopharmacology masterclasses in Dublin, and his lively and interactive CINP seminars in Athens, Cape Town, and Colombo, Sri Lanka. It has been wonderful to hear from many attendees at these events how they were captivated and inspired by Brian's social commitment, engaging delivery, and compendious knowledge. Indeed, he will be missed.</p>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"39 2","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hup.2894","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Psychopharmacology: Clinical and Experimental","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hup.2894","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Ní bheidh a leithéid ann arís’ (‘we won't see his like again’). Thus concluded the warm tribute to Professor Brian Leonard, posted on the British Association for Psychopharmacology website, on the sad news of his passing, after a short illness, in the final week of 2023 (see www.bap.org.uk). Brian was a former President of both the BAP and the Collegium Internationale Neuropsychopharmacologicum (CINP) and served as Editor-in-Chief of Human Psychopharmacology between 1994 and 1999 (succeeding the Founding Editor Guy Edwards, whose obituary was published last year: see Cowen, 2023). During his Editorship, the journal flourished in terms of its scientific content, international contributors, readership and impact.

Born in 1936, Brian became a leading figure in psychopharmacological research, education and training, over 50 years. After working at Nottingham University (1962–1968), and in the pharmaceutical industry (1968–1974, first at ICI Ltd, then Organon Laboratories), he became Founding Professor and Head of the Department of Pharmacology at University College Galway in 1974, continuing there until 1999, when he ‘retired’. He held Professor Emeritus status at the University of Galway, and a Visiting Professorship at the University of Maastricht from 2002, and an Honorary Professorship at Ludwig Maximilian University, Munich since 2007. He continued publishing scientific articles until the final months of 2023. His wide-ranging and influential research encompassed studies of anxiolytic and antidepressant compounds, the neurobiology of affective disorders, alcohol use disorders, and dementia, and he was an early pioneer in the realm of psychoneuroimmunology.

His former colleagues draw attention to his pioneering research in the development and characterisation of animal models of depression (most notably the olfactory bulbectomy model), and in preclinical studies of the pharmacology of antidepressants, anxiolytics, and other psychotropics: and his major contributions to investigating biomarkers of major psychiatric disorders, the metabolic syndrome in depression and schizophrenia, and in psychoneuroimmunology, where he was one of the first to recognise, investigate, and promote the importance of the brain-immune axis in depression and schizophrenia. He received the BAP Lifetime Achievement Award in 2008.

Brian was a truly inspirational lecturer, combining his extensive knowledge of pharmacology with panache and cheeky humour, encouraging many to pursue careers in clinical and experimental psychopharmacology and translational and applied neuroscience. After notional ‘retirement’ he travelled widely, in particular to low and middle income countries in Africa and Asia, lecturing to international colleagues and inspiring the emerging generations of academic and clinical researchers. He received the CINP Arvid Carlsson medal for education in 2012. In addition, Brian had a lifelong passion for challenging socioeconomic disadvantage, discrimination and other societal injustices, and would engage in insightful and lively political discussions whenever needed.

Brian kindly supported my research and clinical interests in anxiety and depression at a pivotal career stage; and later encouraged me to become Editor of this journal. He also invited me to contribute to his periodic psychopharmacology masterclasses in Dublin, and his lively and interactive CINP seminars in Athens, Cape Town, and Colombo, Sri Lanka. It has been wonderful to hear from many attendees at these events how they were captivated and inspired by Brian's social commitment, engaging delivery, and compendious knowledge. Indeed, he will be missed.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
布莱恩-伦纳德教授:《人类精神药理学》前主编。
Ní bheidh a leithéid ann arís"("我们不会再见到他这样的人了")。布莱恩-伦纳德教授于2023年的最后一周因病逝世,英国精神药理学协会网站上发布了对他的热情悼念(见www.bap.org.uk)。布莱恩曾任英国精神药理学协会和国际神经精神药理学学会(CINP)主席,并在1994年至1999年间担任《人类精神药理学》主编(接替创刊主编盖伊-爱德华兹(Guy Edwards),爱德华兹的讣告已于去年发布:见Cowen, 2023)。布莱恩出生于 1936 年,50 多年来一直是精神药理学研究、教育和培训领域的领军人物。他曾在诺丁汉大学(1962-1968 年)和制药业工作(1968-1974 年,先在 ICI 有限公司,后在 Organon 实验室),1974 年成为戈尔韦大学学院药理学系的创始教授和系主任,一直工作到 1999 年 "退休"。他在戈尔韦大学担任名誉教授,2002 年起在马斯特里赫特大学担任客座教授,2007 年起在慕尼黑路德维希-马克西米利安大学担任名誉教授。直到 2023 年的最后几个月,他还在继续发表科学文章。他的研究范围广泛,影响深远,包括抗焦虑和抗抑郁化合物、情感障碍的神经生物学、酒精使用障碍和痴呆症的研究,他还是精神神经免疫学领域的早期先驱。他的前同事提请注意他在抑郁症动物模型(最著名的是嗅球切除术模型)的开发和特征描述方面的开创性研究,以及在抗抑郁药、抗焦虑药和其他精神药物药理学的临床前研究方面的开创性研究:他在研究主要精神疾病的生物标志物、抑郁症和精神分裂症的代谢综合征以及精神神经免疫学方面做出了重大贡献,是最早认识、研究和宣传大脑免疫轴在抑郁症和精神分裂症中的重要性的人之一。布莱恩是一位真正具有启发性的讲师,他将丰富的药理学知识与幽默风趣的语言相结合,鼓励许多人投身于临床和实验精神药理学以及转化和应用神经科学领域。名义上 "退休 "后,他四处奔波,特别是到非洲和亚洲的中低收入国家,为国际同行讲学,激励新一代学术和临床研究人员。2012年,他获得了CINP阿尔维德-卡尔松教育奖章。此外,布莱恩毕生热衷于挑战社会经济劣势、歧视和其他社会不公正现象,并会在必要时参与深刻而热烈的政治讨论。在我职业生涯的关键阶段,布莱恩善意地支持了我在焦虑和抑郁方面的研究和临床兴趣;后来,他还鼓励我成为本期刊的编辑。他还邀请我参加他在都柏林定期举办的精神药理学大师班,以及在雅典、开普敦和斯里兰卡科伦坡举办的生动活泼、互动性强的 CINP 研讨会。在这些活动中,我们从许多与会者那里听到了他们是如何被布莱恩的社会责任感、引人入胜的演讲和渊博的知识所吸引和启发的,这真是太好了。我们确实会怀念他。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
34
审稿时长
6-12 weeks
期刊介绍: Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal: -All aspects of clinical psychopharmacology- Efficacy and safety studies of novel and standard psychotropic drugs- Studies of the adverse effects of psychotropic drugs- Effects of psychotropic drugs on normal physiological processes- Geriatric and paediatric psychopharmacology- Ethical and psychosocial aspects of drug use and misuse- Psychopharmacological aspects of sleep and chronobiology- Neuroimaging and psychoactive drugs- Phytopharmacology and psychoactive substances- Drug treatment of neurological disorders- Mechanisms of action of psychotropic drugs- Ethnopsychopharmacology- Pharmacogenetic aspects of mental illness and drug response- Psychometrics: psychopharmacological methods and experimental design
期刊最新文献
Issue Information Antipsychotic-Treated Schizophrenia Patients Develop Inflammatory and Oxidative Responses Independently From Obesity: However, Metabolic Disturbances Arise From Schizophrenia-Related Obesity Patient outcome following selective serotonin reuptake inhibitor prescribing in primary care in Wales (UK) Issue Information Safety and efficacy of Withania somnifera for anxiety and insomnia: Systematic review and meta-analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1